Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Kewaunee Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KEQU is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: KEQU's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: KEQU underperformed the US Medical Equipment industry which returned 19.1% over the past year.
Return vs Market: KEQU underperformed the US Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kewaunee Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWe Think Kewaunee Scientific (NASDAQ:KEQU) Has A Fair Chunk Of Debt
6 months ago | Simply Wall StDid You Manage To Avoid Kewaunee Scientific's (NASDAQ:KEQU) Painful 59% Share Price Drop?
7 months ago | Simply Wall StDo Institutions Own Kewaunee Scientific Corporation (NASDAQ:KEQU) Shares?
Is Kewaunee Scientific undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KEQU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KEQU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KEQU is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: KEQU is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KEQU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KEQU is good value based on its PB Ratio (0.7x) compared to the US Medical Equipment industry average (4.5x).
How is Kewaunee Scientific forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kewaunee Scientific has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Kewaunee Scientific's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Healthcare industry.
How has Kewaunee Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KEQU is currently unprofitable.
Growing Profit Margin: KEQU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KEQU is unprofitable, and losses have increased over the past 5 years at a rate of 38.4% per year.
Accelerating Growth: Unable to compare KEQU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KEQU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: KEQU has a negative Return on Equity (-15%), as it is currently unprofitable.
How is Kewaunee Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: KEQU's short term assets ($58.5M) exceed its short term liabilities ($30.7M).
Long Term Liabilities: KEQU's short term assets ($58.5M) exceed its long term liabilities ($18.3M).
Debt to Equity History and Analysis
Debt Level: KEQU's debt to equity ratio (22.3%) is considered satisfactory.
Reducing Debt: KEQU's debt to equity ratio has reduced from 25.1% to 22.3% over the past 5 years.
Debt Coverage: KEQU's debt is not well covered by operating cash flow (15.3%).
Interest Coverage: Insufficient data to determine if KEQU's interest payments on its debt are well covered by EBIT.
What is Kewaunee Scientific current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KEQU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KEQU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KEQU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KEQU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: KEQU is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KEQU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Hull (44 yo)
Mr. Thomas D. Hull, III, has been President and Chief Executive Officer at Kewaunee Scientific Corporation since March 11, 2019 and served as its Chief Financial Officer since November 1, 2015 until April ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD674.03K) is about average for companies of similar size in the US market ($USD561.31K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
|VP of Finance||1.58yrs||US$512.96k||0.061% |
|Vice President of Sales & Marketing - Americas||2.33yrs||US$333.87k||0.027% |
|Vice President of Human Resources||11.42yrs||no data||0.13% |
|MD of International Operations & VP of Kewaunee Scientific Corporation Singapore Pte. Ltd.||no data||no data||no data|
|Director of Metal Plant Operations and Facilities||4.58yrs||US$260.43k||no data|
Experienced Management: KEQU's management team is considered experienced (2.3 years average tenure).
|Independent Director||5.58yrs||US$92.00k||0.31% |
|Independent Chairman||1.75yrs||US$94.50k||4.84% |
|Independent Director||25.75yrs||US$87.00k||1.96% |
|Independent Director||7.42yrs||US$87.00k||0.83% |
|Independent Director||9.5yrs||US$89.50k||0.53% |
Experienced Board: KEQU's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Kewaunee Scientific Corporation's company bio, employee growth, exchange listings and data sources
- Name: Kewaunee Scientific Corporation
- Ticker: KEQU
- Exchange: NasdaqGM
- Founded: 1906
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$26.233m
- Shares outstanding: 2.76m
- Website: https://www.kewaunee.com
Number of Employees
- Kewaunee Scientific Corporation
- 2700 West Front Street
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KEQU||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 1980|
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates in two segments, Domestic and International. Its products ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/01 23:06|
|End of Day Share Price||2020/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.